Curcumin Suppresses Growth of Recurrent Colorectal Adenoma After Endoscopic Resection: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial
Authors:
- Tetsuji TakayamaTTTetsuji Takayama
- Koichi OkamotoKOKoichi Okamoto
- Hideki IshikawaHIHideki Ishikawa
- Kaizo KagemotoKKKaizo Kagemoto
- Tatsuhisa YasakaTYTatsuhisa Yasaka
- Takashi HisabeTHTakashi Hisabe
- Toyotaka KasaiTKToyotaka Kasai
- Masaya KubotaMKMasaya Kubota
- Masahito ShimizuMasahito Shimizu
- Tomoyuki AbeTATomoyuki Abe
- 28 August 2026
- journal article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Abstract
INTRODUCTION: Experimental and limited clinical studies suggest that curcumin has chemopreventive activity in the colorectum. This large-scale clinical trial evaluated the efficacy and safety of curcumin in patients with previously endoscopically resected colorectal neoplasia. METHODS: This randomized, double-blind, placebo-controlled multicenter trial enrolled patients with previously resected colorectal neoplasia. Eligible patients were randomly assigned (1:1), using a stratified, computer-generated scheme to receive oral submicron-powdered curcumin (Theracurmin; 180 mg twice daily) or identical placebo capsules for 2 years. All analyses were performed according to a modified intention-to-treat principle including all randomly assigned patients who underwent the 2-year colonoscopy. RESULTS: Between April 1, 2016, and March 31, 2020, 577 patients were randomly assigned to curcumin (n = 287) or placebo groups (n = 290). The detection rate of recurrent colorectal adenomas at 2 years, the primary end point, did not differ significantly between groups (risk ratio 0.98; 95% confident interval 0.82–1.16). However, the detection rate of adenomas ≥6 mm, a prespecified lesion category recommended for endoscopic resection in Japanese guidelines, was significantly lower with curcumin (risk ratio, 0.56; 95% confident interval, 0.33–0.95; P = 0.04). The per-patient number of adenomas ≥6 mm was also significantly lower ( P = 0.03), and the median size of all detected adenomas was significantly smaller in the curcumin group ( P = 0.003). The inhibitory effect seemed more pronounced in patients with higher baseline adenoma burden and in men in exploratory analyses. Treatment-related adverse events were infrequent and mild. DISCUSSION: Curcumin inhibited the growth of recurrent colorectal adenomas, despite no significant reduction in the overall incidence of recurrence. This is the first large-scale randomized clinical trial demonstrating the suppressive efficacy of curcumin against colorectal neoplasia, and also highlighting the importance of incorporating growth-related endpoints, in addition to incidence-based or detection-based end points, in chemoprevention studies (jRCTs061180079).Keywords
Funding Information
- Ministry of Agriculture, Forestry and Fisheries (16808863)
- Theravalues Corporation
This publication has 37 references indexed in Scilit:
- Evidence-based clinical practice guidelines for management of colorectal polypsJournal of Gastroenterology, 2021
- The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexesMolecular Nutrition & Food Research, 2014
- A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin®) in cancer patientsCancer Chemotherapy and Pharmacology, 2013
- Curcumin induces permanent growth arrest of human colon cancer cells: Link between senescence and autophagyMechanisms of Ageing and Development, 2012
- Inhibition of the NF-κB signaling pathway by the curcumin analog, 3,5-Bis(2-pyridinylmethylidene)-4-piperidone (EF31): Anti-inflammatory and anti-cancer propertiesInternational Immunopharmacology, 2012
- Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteersCancer Chemotherapy and Pharmacology, 2011
- ANTIOXIDANT AND ANTI-INFLAMMATORY PROPERTIES OF CURCUMIN2007
- A two generation reproductive toxicity study with curcumin, turmeric yellow, in Wistar ratsFood and Chemical Toxicology, 2007
- Combination Treatment With Curcumin and Quercetin of Adenomas in Familial Adenomatous PolyposisClinical Gastroenterology and Hepatology, 2006
- Curcumin inhibits the mammalian target of rapamycin‐mediated signaling pathways in cancer cellsInternational Journal of Cancer, 2006